Food and Drug Administration Commissioner Marty Makary is resigning from his position Tuesday, a White House official confirmed to Fox News Digital.
The official said the resignation relates to "process at the FDA" rather than any specific issue, adding there is "no bad blood" between President Donald Trump and the outgoing commissioner.
Kyle Diamantis, FDA deputy commissioner for Food, will serve as acting commissioner, Fox News Digital reported.
Health and Human Services Secretary Robert F. Kennedy Jr. pushed for Makary's resignation, according to the White House official.
Makary was set to testify before the Senate Appropriations Committee on Wednesday regarding FDA operations.
What the Left Is Saying
Progressive groups have raised concerns about leadership instability at the FDA during an ongoing transition period in federal health agencies.
Public health advocates worry that frequent turnover at the agency could disrupt drug approval processes and slow responses to emerging health threats.
Some Democratic lawmakers have noted that Makary's departure follows a broader pattern of upheaval across health-related agencies under the current administration.
Health policy experts say consistent leadership is important for maintaining regulatory continuity in an agency responsible for approving pharmaceuticals and medical devices used by millions of Americans.
What the Right Is Saying
Pro-life advocates and supporters of the Make America Healthy Again movement had grown increasingly frustrated with Makary's handling of several high-profile FDA decisions.
"President Trump and Health and Human Services Secretary Kennedy must end this now, remove Commissioner Makary, stop the mail order abortion scheme, and pull these child-killing drugs from the market," said Live Action President Lila Rose in a statement to Fox News Digital.
A Trump administration official told Fox News Digital earlier in May that Makary's comments and actions had told "every pro-life advocate their concerns are an afterthought."
"What a mess Makary turned out to be," the official said, adding that his "arrogance is stunning."
Susan B. Anthony Pro-Life America President Marjorie Dannenfelser told The Wall Street Journal earlier in May that "Trump is the problem" when it comes to abortion issues falling off for Republicans.
What the Numbers Show
Makary's tenure placed him at the center of debates over mifepristone, an abortion medication that generated significant legal and political controversy.
Under Makary's leadership, the FDA approved a new generic version of mifepristone last year while leaving in place rules allowing the drug to be prescribed online and shipped through mail.
Pro-life groups had pushed for reversal of Biden-era rules permitting mail-order prescriptions but found the agency moving slowly on their priorities.
Makary's resignation follows other high-profile departures this year, including former Homeland Security Secretary Kristi Noem and former Attorney General Pam Bondi.
The Bottom Line
Makary's exit marks another leadership change within Trump's administration as it pursues its health policy agenda heading into the midterm election cycle.
The appointment of Diamantis as acting commissioner means a temporary leader will oversee FDA operations while the White House searches for a permanent replacement.
Pro-life advocates are expected to push aggressively for faster action on reversing mifepristone access rules under new leadership.
The timing of Makary's resignation, one day before his scheduled Senate testimony, may prompt questions from lawmakers about the circumstances surrounding his departure.